Cargando…
Ex Vivo Gene Therapy Treats Bone Complications of Mucopolysaccharidosis Type II Mouse Models through Bone Remodeling Reactivation
Mucopolysaccharidosis type II is a disease caused by organ accumulation of glycosaminoglycans due to iduronate 2-sulfatase deficiency. This study investigated the pathophysiology of the bone complications associated with mucopolysaccharidosis II and the effect of lentivirus-mediated gene therapy of...
Autores principales: | Wada, Miho, Shimada, Yohta, Iizuka, Sayoko, Ishii, Natsumi, Hiraki, Hiromi, Tachibana, Toshiaki, Maeda, Kazuhiro, Saito, Mitsuru, Arakawa, Shoutaro, Ishimoto, Takuya, Nakano, Takayoshi, Ida, Hiroyuki, Ohashi, Toya, Kobayashi, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567932/ https://www.ncbi.nlm.nih.gov/pubmed/33102618 http://dx.doi.org/10.1016/j.omtm.2020.09.012 |
Ejemplares similares
-
TFEB overexpression promotes glycogen clearance of Pompe disease iPSC-derived skeletal muscle
por: Sato, Yohei, et al.
Publicado: (2016) -
Metabolomic Profiling of Pompe Disease‐Induced Pluripotent Stem Cell‐Derived Cardiomyocytes Reveals That Oxidative Stress Is Associated with Cardiac and Skeletal Muscle Pathology
por: Sato, Yohei, et al.
Publicado: (2016) -
Frequency of de novo mutations in Japanese patients with Fabry disease
por: Kobayashi, Masahisa, et al.
Publicado: (2014) -
Bone mineral density in mucopolysaccharidosis IVB
por: Kubaski, Francyne, et al.
Publicado: (2016) -
Mass spectrometric quantitation of AGEs and enzymatic crosslinks in human cancellous bone
por: Arakawa, Shoutaro, et al.
Publicado: (2020)